A Study to Evaluate the Long-term Safety and Efficacy of Deucravacitinib in Participants With Crohn's Disease or Ulcerative Colitis

Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)

Number of participants experiencing AEs, SAEs, AEs leading to study discontinuation, and AEs of interest (AEIs). An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. SAEs is any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires inpatient hospitalization; results significant disability; or is a congenital anomaly/birth defect. TEAEs are defined as AEs with an onset date on or after the first dose of study treatment up to 30 days after the last dose of study treatment in the study, or if a pre-existing condition worsens in severity or becomes serious after receiving the first dose of study treatment

Time frame: From first dose to 30 days post last dose (Up to 110 weeks)

Number of Participants With Laboratory Abnormalities

Number of participants experiencing abnormalities in laboratory testing including chemistry, hematology, and renal.

Time frame: From first dose to 30 days post last dose (Up to 110 weeks)

Number of Participants With Electrocardiogram (ECG) Abnormalities

Time frame: From first dose to 30 days post last dose (Up to 110 weeks)

Number of Participants With Vital Signs Abnormalities

Time frame: From first dose to 30 days post last dose (Up to 110 weeks)

Change From Baseline in Laboratory Parameters

Change from baseline in laboratory parameters including lipid profile, chemistry liver function, chemistry (other), and chemistry renal function

Time frame: Baseline, Week 12, Week 108

Change From Baseline in Electrocardiogram (ECG) Parameters - ECG Mean Heart Rate